← vista completa

Publicado el 1 de agosto de 2002 | http://doi.org/10.5867/medwave.2002.07.2331

Intestino irritable

Irritable bowel

Ana María Madrid Silva

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Ana María Madrid Silva

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Madrid Silva AM. Irritable bowel. Medwave 2002;2(10):e2331 doi: 10.5867/medwave.2002.07.2331

Envío 01/01/1970

Aceptación 01/01/1970

Publicación 01/08/2002

Métricas

Vistas en HTML

150

Descargas en PDF

15

Total

165

% Descargas en PDF

10%

Ver detalle

Notas

Referencias

  1. Gershon MD. Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13(suppl 2):15-30 (10).
  2. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999 Mar;44(3):400-6. | CrossRef | PubMed
  3. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978 Sep 2;2(6138):653-4. | CrossRef | PubMed
  4. Thompson WG, Creed F, Drossman DA, Heaton KW, Mazzacca G. Functional bowel disease and functional abdominal pain. Gastroenterology International 1992; 5:75-91
  5. Thompson WG. Gastrointestinal symptoms in the irritable bowel compared with peptic ulcer and inflammatory bowel disease. Gut. 1984 Oct;25(10):1089-92. | CrossRef | PubMed
  6. Shuster M. Gastrointestinal Disorders of Function: The Therapeutic Potential of Serotonin Gastroenterology Treatment Updates 2000 Medscape, Inc
  7. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for the development of the irritable bowel syndrome: a postal survey of patients. BMJ. 1997 Mar 15;314(7083):779-82. | PubMed
  8. Smith RC, Greenbaum DS, Vancouver JB, Henry RC, Reinhart MA, Greenbaum RB, et al. Gender differences in Manning criteria in the irritable bowel s�ndrome. Gastroenterology. 1991 Mar;100(3):591-5. | PubMed
  9. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics and referral. Gut. 2000 Jan;46(1):78-82. | CrossRef | PubMed
  10. Shaw AD, Davies GJ. Lactose Intolerance: Problems in Diagnosis and Treatment.[Review]. J Clin Gastroenterol. J Clin Gastroenterol. 1999 Apr;28(3):208-16. | CrossRef | PubMed
  11. Guthrie E, Creed F, Dawson D, Tomenson B. A randomised controlled trial of psychotherapy in patients with refractory irritable bowel syndrome Br J Psychiatry. 1993 Sep;163:315-21. | CrossRef | PubMed
  12. Aggarwal A, Cutts TF, Abell TL, Cardoso S, Familoni B, Bremer J, et al. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology. 1994 Apr;106(4):945-50. | PubMed
  13. Palsson O, Turner M, Johnson D. Hypnotherapy for irritable bowel syndrome: symptom improvement and autonomic nervous system effects. Program and abstracts of Digestive Disease Week 2000 May: 21-24.
  14. Efskind PS, Bernklev T, Vatn MH. A double?blind, placebo?controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 1996 May;31(5):463-8. | CrossRef | PubMed
  15. Galatola G, the Italian SeHCAT Multicentre Study Group, The prevalence of the bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine: an uncontrolled open multicentre study. Eur J Gastroenterol Hepatol. 1992;4:533-37.
  16. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract. 1999 Dec;48(12):980-90. | PubMed
  17. Camilleri M. Clinical evidence to support current therapies of irritable bowel syndrome. Aliment Pharmacol Ther. 1999 May;13 Suppl 2:48-53. | CrossRef
  18. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999 Sep;45 Suppl 2:II43-7. | CrossRef | PubMed
  19. American Gastroenterological Association. Medical position statement: Irritable bowel syndrome. Gastroenterology. 1997 Jun;112(6):2118-9. | CrossRef | PubMed
  20. Tack J, Vos R, Broekaert D, et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on colonic tone and sensitivity in man. Program and abstracts of Digestive Disease Week 2000 May:21-24.
  21. Sanger GJ. 5-Hydroxytryptamine and functional bowel disorders. Neurogastroenterol Motil. 1996 Dec;8(4):319-31. | CrossRef
  22. Banner SE, Smith MI, Bywater D, Gaster LM, Sanger GJ. Increased defecation caused by 5-HT4 receptor activation in the mouse. Eur J Pharmacol. 1996 Jul 18;308(2):181-6. | CrossRef
  23. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine 4 receptor agonista initiate the peristaltic reflex in human, rat and guinea pig intestine Gastroenterology. 1998 Aug;115(2):370-80. | CrossRef
  24. Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998 Apr;16(4):1568-73. | PubMed
  25. Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci. 1990 Apr;35(4):477-80. | CrossRef | PubMed
  26. Von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans Gut. 1994 Apr;35(4):536-41. | CrossRef | PubMed
  27. Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron) Digestion. 1996 Nov-Dec;57(6):478-83. | CrossRef | PubMed
  28. Northcutt AR, Camilleri M, Mayer EA et al. Treatment of female irritable bowel syndrome patients with alosetron, a 5-HT3 receptor antagonist. Abstract presented at Digestive Disease Week, 1999 May:15-19.
  29. Miner PB Jr., Nichols T, Silvers DR, Joslyn A, Woods M. The efficacy and safety of prucalopride in patients with chronic constipation. Abstract 22190 En: Digestive Disease Week, 1999 May:15-19
  30. Broeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Effect of prucalopride on GI motility in scleroderma. Abstract G4179 En: Digestive Disease Week, 1999 May:15-19
  31. Farup PG, Hovdenak N, Wetterhus S, Lange OJ, Hovde O, Trondstad R. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol. 1998 Feb;33(2):128-31. | CrossRef
  32. Cann PA, Rovati LC, Smart HL, Spiller RC, Whorwell PJ. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome: a pilot multicentre clinical study. Ann N Y Acad Sci. 1994 Mar 23;713:449-50. | CrossRef | PubMed
  33. Delvaux M, Louvel D, Lagier E, Scherrer B, Abitbol JL, Frexinos J. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel s�ndrome. Gastroenterology. 1999 Jan;116(1):38-45. | CrossRef
  34. Houghton LA, Rogers J, Whorwell PJ, Campbell FC, Williams NS, Goka J. Zamifenacin (UK-76,654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel s�ndrome. Aliment Pharmacol Ther. 1997 Jun;11(3):561-8. | CrossRef | PubMed
  35. Mathias JR, Clench MH, Reeves-Darby VG, Fox LM, Hsu PH, Roberts PH, et al. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double - blind, placebo-controlled study. Dig Dis Sci. 1994 Jun;39(6):1155-62. | CrossRef | PubMed